INO vs OKTA · $88.0M cap vs P/E 84, rev $1.57B
Inovio Pharmaceuticals Inc (INO) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Inovio Pharmaceuticals Inc (INO) is a biotechnology company listed on US.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Latest reported INO revenue for 2026-06-30 was $0. Net income was -$6.0M. INO currently screens at market cap $88.0M.
Latest reported OKTA revenue for 2026-07-31 was $1.57B. Net income was $190.0M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
INO currently screens at market cap $88.0M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the INO and OKTA stock pages for the full models.
Not investment advice.